Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

Anna Bateson, Julio Ortiz Canseco, Timothy D. McHugh, Adam A. Witney, Silke Feuerriegel, Matthias Merker, Thomas A. Kohl, Christian Utpatel, Stefan Niemann, Sonke Andres, Katharina Kranzer, Florian P. Maurer, Arash Ghodousi, Emanuele Borroni, Daniela Maria Cirillo, Maria Wijkander, Juan C. Toro, Ramona Groenheit, Jim Werngren, Diana MachadoMiguel Viveiros, Robin M. Warren, Frederick Sirgel, Anzaan Dippenaar, Claudio U. Koeser, Eugene Sun, Juliano Timm

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)
51 Downloads (Pure)


Objectives: To develop a robust phenotypic antimicrobial susceptibility testing (AST) method with a correctly set breakpoint for pretomanid (Pa), the most recently approved anti-tuberculosis drug. Methods: The Becton Dickinson Mycobacterial Growth Indicator Tube™ (MGIT) system was used at six laboratories to determine the MICs of a phylogenetically diverse collection of 356 Mycobacterium tuberculosis complex (MTBC) strains to establish the epidemiological cut-off value for pretomanid. MICs were correlated with WGS data to study the genetic basis of differences in the susceptibility to pretomanid. Results: We observed ancient differences in the susceptibility to pretomanid among various members of MTBC. Most notably, lineage 1 of M. tuberculosis, which is estimated to account for 28% of tuberculosis cases globally, was less susceptible than lineages 2, 3, 4 and 7 of M. tuberculosis, resulting in a 99th percentile of 2 mg/L for lineage 1 compared with 0.5 mg/L for the remaining M. tuberculosis lineages. Moreover, we observed that higher MICs (≥8 mg/L), which probably confer resistance, had recently evolved independently in six different M. tuberculosis strains. Unlike the aforementioned ancient differences in susceptibility, these recent differences were likely caused by mutations in the known pretomanid resistance genes. Conclusions: In light of these findings, the provisional critical concentration of 1 mg/L for MGIT set by EMA must be re-evaluated. More broadly, these findings underline the importance of considering the global diversity of MTBC during clinical development of drugs and when defining breakpoints for AST.

Original languageEnglish
JournalJournal of Antimicrobial Chemotherapy
Publication statusE-pub ahead of print - 9 Mar 2022


Dive into the research topics of 'Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid'. Together they form a unique fingerprint.

Cite this